Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
200 shown of 7,068 total abstracts
  1. Abstract 13422026-06-04 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-577 study)
    S. Peters, J. Cortes, J. Brahmer, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract 18122026-06-03 · 19:15 CT · E450
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-896
    M. Reck, A. Spira · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract e120022026-06-04 · 21:30 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-18 study)
    M.C. Garassino, N. Rizvi, M. Krop, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  4. Abstract 10912026-06-05 · 19:15 CT · E450
    MONALEESA-764: Kisqali (ribociclib) 1L in HR+ breast cancer
    A. Spira, H. Rugo, G. Curigliano · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract 19652026-06-01 · 21:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-315
    J. Cortes, N. Rizvi, M. Reck, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  6. Abstract 19432026-06-02 · 19:15 CT · Hall B1
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-610
    H. Rugo, M. Reck · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract e120062026-06-02 · 21:15 CT · E450
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-474 study)
    J. Cortes, T. Mok, H. Rugo, et al. · National Cancer Center Japan
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  8. Abstract e120072026-06-04 · 19:45 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-252
    T. Mok, S. Modi, S. Antonia · Cleveland Clinic
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  9. Abstract 17652026-06-04 · 19:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-778
    P. Schmid, S. Peters, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract 11412026-06-02 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-520
    P. Schmid, M.C. Garassino, F. Andre · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract 10912026-06-02 · 14:30 CT · Arie Crown Theater
    IMpower-33: Tecentriq (atezolizumab) 3L+ in TNBC
    S. Antonia, F. Andre, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract 15732026-06-02 · 15:15 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    H. Rugo, C. Saura, P. Schmid · Chinese University of Hong Kong
    Education SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract 18222026-06-02 · 14:15 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    H. Rugo, S. Peters, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  14. Abstract 15582026-06-02 · 21:15 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-599 study)
    P. Schmid, S. Tolaney, S. Modi, et al. · Princess Margaret Cancer Centre
    Education SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract e120142026-06-03 · 16:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-492 study)
    J. Cortes, N. Rizvi, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  16. Abstract 14112026-06-05 · 18:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-675
    M. Krop, P. Schmid, N. Rizvi, et al. · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 19172026-06-01 · 19:15 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    S. Antonia, J. Brahmer, C. Robert, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract 11352026-06-05 · 15:15 CT · S406
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-720
    C. Robert, M. Reck, L. Paz-Ares, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract 13832026-06-05 · 16:30 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-200
    G. Curigliano, P. Schmid, H. Borghaei, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  20. Abstract 15642026-06-03 · 15:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-994
    E. Winer, R. Herbst, M.C. Garassino, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract 15752026-06-03 · 14:30 CT · S100A
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    H. Rugo, T. Mok, P. Schmid, et al. · Institut Gustave Roussy
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract LBA4021LBA2026-06-02 · 13:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-528
    S. Antonia, M. Reck · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  23. Abstract 19882026-06-04 · 18:45 CT · S406
    MONARCH-723: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    M.C. Garassino, E. Winer · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  24. Abstract 19892026-06-05 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-262 study)
    C. Saura, J. Cortes · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  25. Abstract 10292026-06-02 · 20:00 CT · Arie Crown Theater
    DESTINY-Breast-348: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    S. Modi, S. Antonia, F. Andre · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  26. Abstract 13542026-06-01 · 16:00 CT · S100A
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-73 study)
    E. Winer, F. Andre, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  27. Abstract 18802026-06-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-43 study)
    S. Modi, S. Antonia, C. Robert · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  28. Abstract 11902026-06-05 · 16:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-566 study)
    M. Krop, S. Peters, N. Rizvi, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  29. Abstract 14072026-06-01 · 21:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-132
    M. Krop, M. Reck, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  30. Abstract 10842026-06-02 · 16:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-462 study)
    N. Rizvi, H. Borghaei, T. Mok · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  31. Abstract 17772026-06-02 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    C. Saura, M. Krop, E. Winer · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  32. Abstract 17312026-06-02 · 21:00 CT · S100A
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    P. Schmid, E. Winer · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract LBA4032LBA2026-06-02 · 15:00 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    M. Reck, S. Antonia · Institut Gustave Roussy
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  34. Abstract 14752026-06-05 · 20:45 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    P. Schmid, S. Modi, M. Krop · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  35. Abstract 17892026-06-02 · 18:30 CT · S406
    PALOMA-585: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    T. Mok, S. Modi, A. Spira, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  36. Abstract 12282026-06-03 · 15:45 CT · Arie Crown Theater
    MONARCH-277: Verzenio (abemaciclib) 2L in HR+ breast cancer
    N. Rizvi, M. Krop, C. Saura, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  37. Abstract 17602026-06-02 · 13:45 CT · S100A
    Quality of life outcomes with Trodelvy in patients with TNBC
    S. Peters, M. Reck, H. Borghaei · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  38. Abstract 13412026-06-03 · 16:45 CT · Hall B1
    Long-term follow-up of Kisqali adjuvant for HR+ breast cancer: MONALEESA-519
    C. Robert, M.C. Garassino, R. Herbst, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  39. Abstract 12852026-06-02 · 14:30 CT · Hall B1
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-502
    T. Mok, G. Curigliano, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  40. Abstract 17472026-06-04 · 21:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-453 study)
    R. Herbst, L. Paz-Ares, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  41. Abstract 19532026-06-04 · 21:00 CT · Hall B1
    Quality of life outcomes with Tecentriq in patients with TNBC
    G. Curigliano, T. Mok, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  42. Abstract 14222026-06-05 · 16:00 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-410 study)
    F. Andre, E. Winer, S. Tolaney, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  43. Abstract LBA4042LBA2026-06-05 · 21:15 CT · S100A
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-601 study)
    A. Spira, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  44. Abstract 15852026-06-05 · 14:00 CT · S406
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-379
    M. Reck, S. Peters, L. Paz-Ares, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  45. Abstract 13712026-06-05 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-974 study)
    C. Saura, H. Rugo, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  46. Abstract 11042026-06-03 · 19:00 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-65 study)
    M. Reck, N. Rizvi, P. Schmid, et al. · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  47. Abstract 15262026-06-01 · 18:45 CT · Arie Crown Theater
    PALOMA-515: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    M. Krop, S. Modi, F. Andre, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  48. Abstract 15572026-06-02 · 18:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-21
    S. Modi, S. Peters, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  49. Abstract 15102026-06-03 · 21:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-764
    T. Mok, S. Antonia, H. Borghaei · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  50. Abstract 12572026-06-01 · 16:45 CT · S406
    MONALEESA-110: Kisqali (ribociclib) 3L+ in HR+ breast cancer
    A. Spira, S. Modi, C. Saura, et al. · Karolinska Institute
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  51. Abstract LBA4050LBA2026-06-05 · 15:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-848 study)
    S. Modi, H. Borghaei · Dana-Farber Cancer Institute
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 11722026-06-05 · 15:45 CT · S406
    MONARCH-567: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    F. Andre, S. Tolaney, A. Spira, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  53. Abstract 17382026-06-04 · 16:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-619 study)
    C. Saura, C. Robert, M. Krop · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  54. Abstract 18972026-06-04 · 15:15 CT · S406
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-510
    M. Krop, A. Spira · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  55. Abstract 14792026-06-03 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-91
    F. Andre, N. Rizvi, R. Herbst · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  56. Abstract 15562026-06-03 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-234 study)
    H. Rugo, J. Brahmer · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  57. Abstract e120562026-06-05 · 20:00 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-668
    M. Krop, T. Mok, S. Antonia · Dana-Farber Cancer Institute
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  58. Abstract 10662026-06-04 · 18:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-255 study)
    A. Spira, H. Borghaei · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  59. Abstract 16942026-06-03 · 13:45 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-995
    R. Herbst, J. Cortes, H. Borghaei, et al. · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 14952026-06-04 · 14:00 CT · Arie Crown Theater
    DESTINY-Breast-81: Enhertu (trastuzumab deruxtecan) neoadjuvant in HR+ breast cancer
    M. Krop, J. Cortes · MD Anderson Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  61. Abstract 17502026-06-01 · 15:00 CT · Arie Crown Theater
    MONALEESA-571: Kisqali (ribociclib) 2L in HR+ breast cancer
    S. Tolaney, J. Brahmer · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  62. Abstract 18392026-06-01 · 16:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-336 study)
    H. Borghaei, S. Peters · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  63. Abstract 13682026-06-04 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-833
    L. Paz-Ares, M.C. Garassino, F. Andre · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  64. Abstract LBA4063LBA2026-06-05 · 19:15 CT · Hall B1
    IMpower-785: Tecentriq (atezolizumab) neoadjuvant in TNBC
    H. Borghaei, G. Curigliano, R. Herbst · Chinese University of Hong Kong
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 16022026-06-05 · 16:00 CT · E450
    MONARCH-210: Verzenio (abemaciclib) 2L in HR+ breast cancer
    C. Saura, N. Rizvi, H. Borghaei, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  66. Abstract 15332026-06-01 · 19:15 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-180 study)
    J. Cortes, L. Paz-Ares, E. Winer, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  67. Abstract 15582026-06-02 · 21:45 CT · S100A
    IMpower-707: Tecentriq (atezolizumab) 1L in TNBC
    A. Spira, H. Rugo, E. Winer · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 12482026-06-02 · 18:15 CT · S100A
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-746
    P. Schmid, H. Rugo, J. Cortes, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  69. Abstract 18842026-06-01 · 15:45 CT · S406
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-945
    R. Herbst, H. Borghaei · Institut Gustave Roussy
    Education SessionBreast Cancer—Metastatic📄🖼️
  70. Abstract 18522026-06-05 · 20:15 CT · E450
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-246
    S. Modi, S. Peters · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  71. Abstract e120702026-06-05 · 18:45 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-616 study)
    S. Modi, A. Spira, G. Curigliano · Institut Gustave Roussy
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  72. Abstract 10092026-06-05 · 18:30 CT · S100A
    PALOMA-61: Ibrance (palbociclib) 1L in HR+ breast cancer
    A. Spira, N. Rizvi, C. Robert, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  73. Abstract 10512026-06-01 · 15:00 CT · Arie Crown Theater
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    J. Brahmer, T. Mok, E. Winer, et al. · Chinese University of Hong Kong
    Poster SessionBreast Cancer—Metastatic📄🖼️
  74. Abstract 10332026-06-05 · 15:00 CT · E450
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-945 study)
    S. Antonia, J. Cortes · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  75. Abstract 12032026-06-04 · 13:30 CT · S100A
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-649
    F. Andre, S. Antonia, C. Saura, et al. · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  76. Abstract 13872026-06-03 · 15:15 CT · Hall B1
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-197
    N. Rizvi, S. Tolaney · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  77. Abstract 18512026-06-02 · 19:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-890
    M. Krop, J. Cortes · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  78. Abstract 17792026-06-04 · 20:30 CT · S406
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-265 study)
    L. Paz-Ares, F. Andre, J. Cortes, et al. · Royal Marsden Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  79. Abstract 16232026-06-01 · 19:00 CT · Hall B1
    DESTINY-Breast-613: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    C. Saura, N. Rizvi · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  80. Abstract 14322026-06-04 · 15:15 CT · S406
    Long-term follow-up of Tecentriq 1L for TNBC: IMpower-209
    H. Rugo, C. Saura, A. Spira, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  81. Abstract 19142026-06-05 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 1L for HR+ breast cancer: MONARCH-783
    L. Paz-Ares, N. Rizvi, E. Winer · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  82. Abstract 13652026-06-03 · 14:15 CT · Hall B1
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-134
    C. Robert, A. Spira, R. Herbst, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  83. Abstract 18272026-06-04 · 14:15 CT · Arie Crown Theater
    ASCENT-179: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    N. Rizvi, S. Tolaney, T. Mok, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  84. Abstract 19482026-06-03 · 13:15 CT · S406
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-862 study)
    M. Reck, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  85. Abstract 18642026-06-02 · 13:30 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 2L for HR+ breast cancer: MONARCH-891
    S. Modi, J. Cortes, R. Herbst, et al. · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  86. Abstract 17502026-06-01 · 19:30 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-791
    S. Tolaney, G. Curigliano · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  87. Abstract 16832026-06-02 · 18:00 CT · S406
    ASCENT-550: Trodelvy (sacituzumab govitecan) maintenance in TNBC
    M. Reck, F. Andre, M. Krop · Royal Marsden Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract TPS80872026-06-02 · 14:30 CT · E450
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-158
    M.C. Garassino, P. Schmid, A. Spira, et al. · Princess Margaret Cancer Centre
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  89. Abstract 10792026-06-04 · 13:30 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    L. Paz-Ares, M. Reck, H. Borghaei, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  90. Abstract 10702026-06-01 · 16:00 CT · S406
    ASCENT-800: Trodelvy (sacituzumab govitecan) 2L in TNBC
    F. Andre, J. Cortes, M. Krop · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  91. Abstract TPS80902026-06-01 · 18:00 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-130
    F. Andre, M. Krop · Stanford Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  92. Abstract 16822026-06-05 · 14:15 CT · S100A
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-39 study)
    L. Paz-Ares, S. Tolaney, M. Reck, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  93. Abstract 11432026-06-03 · 15:00 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-757 study)
    R. Herbst, S. Tolaney, H. Borghaei, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  94. Abstract 18022026-06-02 · 15:30 CT · E450
    OlympiA-579: Lynparza (olaparib) 1L in HR+ breast cancer
    T. Mok, J. Brahmer, J. Cortes, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  95. Abstract e120942026-06-05 · 16:15 CT · S100A
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-816
    F. Andre, J. Cortes, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  96. Abstract 18752026-06-02 · 13:45 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-577
    G. Curigliano, J. Cortes · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  97. Abstract 12832026-06-03 · 14:00 CT · S406
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-380 study)
    C. Saura, M.C. Garassino, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  98. Abstract 19542026-06-02 · 14:00 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-469
    T. Mok, H. Rugo, F. Andre · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  99. Abstract 15712026-06-02 · 19:45 CT · Hall B1
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-646
    F. Andre, M.C. Garassino, S. Antonia, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  100. Abstract 18512026-06-03 · 19:45 CT · S406
    OlympiA-665: Lynparza (olaparib) adjuvant in HR+ breast cancer
    S. Antonia, N. Rizvi · Chinese University of Hong Kong
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  101. Abstract 19262026-06-01 · 14:00 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-766
    R. Herbst, A. Spira, E. Winer, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  102. Abstract 13062026-06-03 · 16:15 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-14
    T. Mok, S. Antonia, R. Herbst, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionBreast Cancer—Metastatic📄🖼️
  103. Abstract 15792026-06-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-264 study)
    M.C. Garassino, P. Schmid, C. Saura · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  104. Abstract 15242026-06-03 · 14:45 CT · E450
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    H. Rugo, E. Winer, P. Schmid · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
  105. Abstract 16292026-06-03 · 15:15 CT · S406
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    C. Robert, M. Krop, C. Saura, et al. · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  106. Abstract 17812026-06-02 · 14:00 CT · E450
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-548
    N. Rizvi, S. Modi, C. Robert, et al. · Karolinska Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  107. Abstract 15192026-06-05 · 18:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-247
    M. Krop, T. Mok · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  108. Abstract 10042026-06-03 · 18:30 CT · S406
    Long-term follow-up of Keytruda maintenance for TNBC: KEYNOTE-945
    J. Brahmer, S. Modi, S. Antonia · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  109. Abstract 14302026-06-05 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-854 study)
    P. Schmid, J. Cortes · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  110. Abstract 16432026-06-05 · 13:45 CT · S406
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-195
    H. Borghaei, S. Modi, G. Curigliano, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  111. Abstract 12992026-06-01 · 15:45 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-647
    H. Borghaei, M.C. Garassino, J. Brahmer · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  112. Abstract TPS81112026-06-02 · 19:00 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-810
    J. Cortes, G. Curigliano, M. Reck, et al. · Stanford Cancer Institute
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  113. Abstract 11032026-06-04 · 13:30 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-755
    L. Paz-Ares, M.C. Garassino, S. Tolaney, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  114. Abstract e121132026-06-03 · 16:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-381 study)
    M. Krop, M. Reck, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  115. Abstract 13842026-06-05 · 15:00 CT · Hall B1
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-436
    H. Rugo, J. Cortes · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract e121152026-06-05 · 21:45 CT · E450
    PALOMA-244: Ibrance (palbociclib) 1L in HR+ breast cancer
    C. Robert, H. Rugo, F. Andre, et al. · MD Anderson Cancer Center
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  117. Abstract 10542026-06-02 · 19:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-955
    L. Paz-Ares, S. Antonia, C. Saura, et al. · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  118. Abstract LBA4117LBA2026-06-03 · 16:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-478
    M.C. Garassino, H. Borghaei, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  119. Abstract 12622026-06-01 · 16:15 CT · S100A
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-38
    J. Cortes, F. Andre · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  120. Abstract 15662026-06-04 · 15:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-969
    R. Herbst, E. Winer, S. Antonia, et al. · National Cancer Center Japan
    Education SessionBreast Cancer—Metastatic📄🖼️
  121. Abstract LBA4120LBA2026-06-04 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-222
    J. Cortes, S. Antonia · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  122. Abstract 18532026-06-02 · 20:15 CT · Arie Crown Theater
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-640
    S. Modi, M. Reck · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  123. Abstract 15842026-06-03 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-715 study)
    A. Spira, M. Krop, F. Andre · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  124. Abstract 10322026-06-04 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-749
    M. Reck, M.C. Garassino, L. Paz-Ares, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  125. Abstract 14462026-06-05 · 18:45 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-445 study)
    S. Peters, S. Tolaney, N. Rizvi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  126. Abstract 14842026-06-01 · 21:45 CT · S100A
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-684
    C. Robert, M. Reck, M.C. Garassino, et al. · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  127. Abstract LBA4126LBA2026-06-03 · 20:00 CT · Arie Crown Theater
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    R. Herbst, S. Modi, L. Paz-Ares, et al. · Royal Marsden Hospital
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 13962026-06-04 · 16:15 CT · Hall B1
    MONARCH-561: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    H. Borghaei, M.C. Garassino, P. Schmid, et al. · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  129. Abstract 15332026-06-04 · 21:30 CT · S100A
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    S. Peters, S. Tolaney, S. Antonia, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  130. Abstract 18212026-06-05 · 18:00 CT · E450
    Long-term follow-up of Enhertu 2L for HR+ breast cancer: DESTINY-Breast-239
    R. Herbst, S. Peters, P. Schmid · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  131. Abstract 14962026-06-03 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 1L for HR+ breast cancer: MONALEESA-804
    J. Cortes, F. Andre, J. Brahmer, et al. · Mayo Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  132. Abstract 13422026-06-05 · 20:30 CT · S100A
    PALOMA-319: Ibrance (palbociclib) 2L in HR+ breast cancer
    F. Andre, P. Schmid, S. Peters · Mayo Clinic
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  133. Abstract 10652026-06-01 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-855
    S. Peters, C. Robert · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  134. Abstract 10192026-06-05 · 20:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-257
    L. Paz-Ares, E. Winer, N. Rizvi, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  135. Abstract 15382026-06-01 · 14:30 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-562
    G. Curigliano, S. Peters · Vall d'Hebron Institute of Oncology
    Education SessionBreast Cancer—Metastatic📄🖼️
  136. Abstract e121352026-06-05 · 19:45 CT · S100A
    PALOMA-402: Ibrance (palbociclib) 2L in HR+ breast cancer
    M. Krop, S. Tolaney, M. Reck · University of Chicago
    Publication OnlyBreast Cancer—Metastatic📄🖼️
  137. Abstract 12122026-06-05 · 13:15 CT · S406
    Long-term follow-up of Verzenio maintenance for HR+ breast cancer: MONARCH-610
    E. Winer, H. Rugo · MD Anderson Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  138. Abstract 17502026-06-04 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-328 study)
    M.C. Garassino, M. Krop, R. Herbst · Royal Marsden Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  139. Abstract 11042026-06-01 · 18:00 CT · E450
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-997
    P. Schmid, N. Rizvi · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  140. Abstract 16622026-06-02 · 14:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-521
    S. Antonia, M. Krop, A. Spira, et al. · Stanford Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  141. Abstract 17422026-06-05 · 13:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-647
    F. Andre, C. Robert, H. Rugo, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  142. Abstract 14862026-06-03 · 20:30 CT · S100A
    Long-term follow-up of Verzenio adjuvant for HR+ breast cancer: MONARCH-46
    H. Rugo, G. Curigliano, S. Peters, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  143. Abstract 10702026-06-01 · 19:15 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-522
    M. Krop, R. Herbst, S. Antonia, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  144. Abstract 10942026-06-01 · 20:00 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-439
    J. Cortes, F. Andre, G. Curigliano, et al. · Institut Gustave Roussy
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  145. Abstract TPS81442026-06-04 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-7
    R. Herbst, F. Andre, M.C. Garassino · Royal Marsden Hospital
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  146. Abstract LBA4145LBA2026-06-02 · 15:30 CT · S406
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-968
    E. Winer, A. Spira · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  147. Abstract LBA4146LBA2026-06-02 · 14:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-539
    S. Antonia, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Late-Breaking Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract LBA4147LBA2026-06-01 · 14:15 CT · S100A
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-392 study)
    S. Tolaney, H. Borghaei, R. Herbst, et al. · University of Chicago
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  149. Abstract 10072026-06-02 · 19:15 CT · S100A
    ASCENT-235: Trodelvy (sacituzumab govitecan) 1L in TNBC
    H. Rugo, M.C. Garassino, S. Tolaney, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Education SessionBreast Cancer—Metastatic📄🖼️
  150. Abstract 16362026-06-04 · 13:15 CT · S406
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-61
    S. Antonia, P. Schmid · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  151. Abstract 11112026-06-02 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-834
    H. Rugo, J. Brahmer, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  152. Abstract 11172026-06-05 · 13:00 CT · Arie Crown Theater
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-197
    E. Winer, H. Rugo, H. Borghaei, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  153. Abstract 17032026-06-04 · 14:15 CT · E450
    PALOMA-880: Ibrance (palbociclib) maintenance in HR+ breast cancer
    S. Tolaney, C. Saura, P. Schmid · National Cancer Center Japan
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  154. Abstract 17872026-06-05 · 14:30 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-129
    L. Paz-Ares, H. Borghaei, M. Reck, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  155. Abstract 12072026-06-05 · 13:30 CT · S406
    Long-term follow-up of Trodelvy neoadjuvant for TNBC: ASCENT-918
    M. Krop, M. Reck, E. Winer, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  156. Abstract TPS81552026-06-05 · 16:45 CT · S406
    ASCENT-132: Trodelvy (sacituzumab govitecan) 2L in TNBC
    L. Paz-Ares, M. Reck, J. Cortes · Memorial Sloan Kettering Cancer Center
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  157. Abstract 14222026-06-04 · 14:00 CT · Arie Crown Theater
    Long-term follow-up of Ibrance maintenance for HR+ breast cancer: PALOMA-992
    C. Robert, E. Winer · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  158. Abstract 10012026-06-04 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-795
    N. Rizvi, M. Reck · Karolinska Institute
    Education SessionBreast Cancer—Metastatic📄🖼️
  159. Abstract 12162026-06-04 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-949 study)
    A. Spira, S. Modi, S. Tolaney · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  160. Abstract 11222026-06-03 · 14:00 CT · E450
    PALOMA-914: Ibrance (palbociclib) 2L in HR+ breast cancer
    J. Cortes, F. Andre, S. Antonia, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  161. Abstract 14682026-06-04 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy adjuvant for TNBC: ASCENT-819
    S. Peters, S. Modi, T. Mok, et al. · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  162. Abstract TPS81612026-06-01 · 16:45 CT · S406
    DESTINY-Breast-834: Enhertu (trastuzumab deruxtecan) maintenance in HR+ breast cancer
    C. Robert, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  163. Abstract 15492026-06-02 · 21:15 CT · E450
    PALOMA-970: Ibrance (palbociclib) 1L in HR+ breast cancer
    R. Herbst, J. Brahmer, S. Antonia, et al. · University of Chicago
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  164. Abstract 15692026-06-04 · 20:00 CT · S100A
    PALOMA-300: Ibrance (palbociclib) 2L in HR+ breast cancer
    P. Schmid, S. Tolaney · Peter MacCallum Cancer Centre
    Poster SessionBreast Cancer—Metastatic📄🖼️
  165. Abstract 16602026-06-03 · 14:30 CT · Hall B1
    PALOMA-751: Ibrance (palbociclib) adjuvant in HR+ breast cancer
    N. Rizvi, R. Herbst, P. Schmid, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  166. Abstract 14272026-06-01 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-959 study)
    E. Winer, M.C. Garassino, S. Tolaney, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  167. Abstract 13852026-06-02 · 15:45 CT · S100A
    IMpower-272: Tecentriq (atezolizumab) 1L in TNBC
    M. Krop, F. Andre, M. Reck, et al. · Cleveland Clinic
    Poster SessionBreast Cancer—Metastatic📄🖼️
  168. Abstract 16272026-06-05 · 21:30 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-707
    F. Andre, P. Schmid, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  169. Abstract 19042026-06-05 · 13:30 CT · S406
    Long-term follow-up of Tecentriq adjuvant for TNBC: IMpower-189
    S. Modi, F. Andre, M. Krop, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  170. Abstract 19612026-06-04 · 16:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-965
    A. Spira, H. Rugo, P. Schmid, et al. · Chinese University of Hong Kong
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  171. Abstract 19142026-06-02 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-602 study)
    J. Brahmer, G. Curigliano, N. Rizvi, et al. · National Cancer Center Japan
    Poster SessionBreast Cancer—Metastatic📄🖼️
  172. Abstract 11722026-06-04 · 13:45 CT · E450
    ASCENT-630: Trodelvy (sacituzumab govitecan) 2L in TNBC
    M. Reck, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  173. Abstract 10852026-06-03 · 14:00 CT · Hall B1
    IMpower-978: Tecentriq (atezolizumab) maintenance in TNBC
    T. Mok, M. Reck, S. Tolaney · Johns Hopkins Kimmel Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  174. Abstract 18982026-06-03 · 13:00 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-635
    G. Curigliano, M. Krop, F. Andre · Massachusetts General Hospital
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  175. Abstract 18342026-06-05 · 21:00 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-298
    S. Tolaney, M.C. Garassino, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  176. Abstract 16862026-06-04 · 15:15 CT · S406
    Tecentriq plus chemotherapy in previously untreated TNBC: updated analysis from IMpower-893
    N. Rizvi, H. Borghaei, S. Modi, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  177. Abstract 12432026-06-01 · 15:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-172
    A. Spira, L. Paz-Ares, M. Krop · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  178. Abstract 11022026-06-01 · 14:15 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-655
    N. Rizvi, T. Mok, S. Antonia, et al. · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  179. Abstract 10092026-06-03 · 13:45 CT · Hall B1
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-933
    S. Modi, M.C. Garassino, S. Peters, et al. · Dana-Farber Cancer Institute
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  180. Abstract 18572026-06-03 · 20:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-282
    H. Borghaei, S. Peters, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  181. Abstract 14142026-06-05 · 21:00 CT · E450
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-171
    E. Winer, M. Reck, H. Borghaei, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  182. Abstract 17332026-06-03 · 15:00 CT · E450
    ASCENT-958: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    M. Krop, C. Saura, J. Cortes, et al. · Massachusetts General Hospital
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  183. Abstract 18282026-06-01 · 20:45 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-360
    L. Paz-Ares, S. Peters, M. Reck, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  184. Abstract 13392026-06-03 · 21:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-244
    T. Mok, C. Robert · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  185. Abstract 12452026-06-04 · 19:15 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-344
    M.C. Garassino, M. Reck, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  186. Abstract 14812026-06-03 · 15:45 CT · Arie Crown Theater
    MONALEESA-3: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    G. Curigliano, A. Spira, M. Krop, et al. · Mayo Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  187. Abstract 13212026-06-05 · 19:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-716 study)
    J. Brahmer, H. Rugo, P. Schmid · University of Chicago
    Poster SessionBreast Cancer—Metastatic📄🖼️
  188. Abstract 14422026-06-04 · 21:45 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-228 study)
    S. Modi, J. Brahmer, H. Rugo, et al. · Dana-Farber Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  189. Abstract 19112026-06-04 · 21:15 CT · Arie Crown Theater
    OlympiA-667: Lynparza (olaparib) adjuvant in HR+ breast cancer
    S. Peters, F. Andre, M. Krop · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  190. Abstract 17382026-06-03 · 20:45 CT · E450
    DESTINY-Breast-861: Enhertu (trastuzumab deruxtecan) 2L in HR+ breast cancer
    C. Robert, J. Brahmer, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  191. Abstract 10132026-06-02 · 21:00 CT · Hall B1
    Long-term follow-up of Kisqali 2L for HR+ breast cancer: MONALEESA-325
    M. Krop, M. Reck, T. Mok, et al. · Stanford Cancer Institute
    Poster SessionBreast Cancer—Metastatic📄🖼️
  192. Abstract 15622026-06-02 · 16:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-420 study)
    S. Tolaney, H. Borghaei, N. Rizvi · Massachusetts General Hospital
    Poster SessionBreast Cancer—Metastatic📄🖼️
  193. Abstract 10682026-06-03 · 19:45 CT · S100A
    IMpower-757: Tecentriq (atezolizumab) adjuvant in TNBC
    L. Paz-Ares, T. Mok, A. Spira · Cleveland Clinic
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  194. Abstract 10002026-06-02 · 15:15 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-481
    A. Spira, M. Reck, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  195. Abstract 14052026-06-05 · 18:00 CT · Hall B1
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-504
    T. Mok, E. Winer, H. Rugo, et al. · Princess Margaret Cancer Centre
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  196. Abstract 18722026-06-04 · 20:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-208 study)
    A. Spira, N. Rizvi, R. Herbst, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionBreast Cancer—Metastatic📄🖼️
  197. Abstract 10182026-06-05 · 15:45 CT · Arie Crown Theater
    MONARCH-318: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Tolaney, M. Reck, C. Saura, et al. · MD Anderson Cancer Center
    Poster Discussion SessionBreast Cancer—Metastatic📄🖼️
  198. Abstract 13552026-06-01 · 15:30 CT · S406
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-993 study)
    C. Saura, E. Winer · Massachusetts General Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  199. Abstract TPS81982026-06-02 · 21:15 CT · S100A
    Long-term follow-up of Enhertu adjuvant for HR+ breast cancer: DESTINY-Breast-980
    H. Borghaei, F. Andre · Massachusetts General Hospital
    Trials in Progress Poster SessionBreast Cancer—Metastatic📄🖼️
  200. Abstract 10712026-06-01 · 15:15 CT · Arie Crown Theater
    PALOMA-191: Ibrance (palbociclib) 1L in HR+ breast cancer
    J. Cortes, S. Modi, S. Antonia, et al. · Institut Gustave Roussy
    Poster SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.